drugset / Trial / NCT06411210
Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment
Phase 2
Recruiting
54 enrolled
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collabNovo Nordisk A/S · collab
RandomizedParallel-groupDouble-blindBasic science
Summary
More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. GLP-1 analogues are anti-obesity medications that are cardioprotective in adults with type 2 diabetes, however evaluation of these agents in people with T1D has been limited to glycemic outcomes. Investigators aim to study the impact of GLP-1 analogue obesity treatment on markers of cardiometabolic risk in young adults with T1D and obesity.
Timeline
- Start
- 2024-07-16
- Primary completion
- 2028-04-30
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Semaglutide | Peptide | 2.4 mg | — |